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Background: There are some reports about the antitumor effects of statins in these days. Statins
decrease the level of cholesterol in the blood by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A
reductase. Inhibition of this enzyme decreases intracellular cholesterol synthesis. Thus, the expression of
low-density lipoprotein receptor (LDLr) is increased to import more cholesterol from the bloodstream. In
this study, we assessed the effects of statins on the proliferation of prostate cancer cells, and studied the
relationship between the expression of LDLr and the effects of statins.
Methods: Simvastatin was used in the experiments. We studied the effect of simvastatin on PC-3 and
LNCaP cell proliferation using the MTS assay, and evaluated the expression of LDLr after administration of
simvastatin by quantitative polymerase chain reaction and Western blotting. Intracellular cholesterol
levels in the prostate cancer cells were measured after administration of simvastatin. Furthermore, small
interfering RNA (siRNA) was used to knockdown the gene expression of LDLr.
Results: In PC-3 cells, simvastatin inhibited cell proliferation. In LNCaP cells, only a high concentration of
simvastatin (100mM) inhibited cell proliferation. In LNCaP cells, the protein level of LDLr was increased by
simvastatin. In PC-3 cells, the protein levels of LDLr were unregulated. In PC-3 cells, but not in LNCaP
cells, intracellular cholesterol levels were signiﬁcantly decreased by simvastatin. After knocking down
LDLr expression by siRNA, intracellular cholesterol levels were decreased, and cell proliferation was
inhibited by simvastatin in LNCaP cells.
Conclusion: Simvastatin inhibited prostate cancer cell growth by decreasing cellular cholesterol and
could be more effective in androgen-independent prostate cancer, where there is loss of regulation of
LDLr expression. LDLr was shown to play an important role in the statin-induced inhibition of prostate
cancer cell proliferation. These results suggest that future studies evaluating the cholesterol-lowering
effects of statin may lead to new approaches to the prevention and treatment of prostate cancer.
Copyright © 2016 Asian Paciﬁc Prostate Society, Published by Elsevier. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Hyperlipidemia attracts much attention today. One of the key
therapies for hyperlipidemia involves use of statins. Statins
decrease the level of cholesterol in the blood by inhibiting 3-
hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase in
the mevalonate pathway.1 Recently, some reports have demon-
strated the antitumor effects of statins. Regarding prostate cancer
some clinical studies, however, have presented controversialGunma University Graduate
, Gunma 371-8511, Japan.
).
ciﬁc Prostate Society, Published bresults.2,3 In vitro, statins have biological effects that inhibit pros-
tate carcinogenesis (e.g., cell cycle arrest, apoptosis induction, and
inhibition of lipid raft signaling).4,5 However, the actual mecha-
nisms underlying their antitumor effects remain unclear.
Low-density lipoprotein receptor (LDLr) plays an important role
in the serum cholesterol-lowering effects of statins. Statins upre-
gulate the expression of LDLr and increase clearance of LDL from
the bloodstream. In normal cells, the expression of LDLr is depen-
dent on intracellular cholesterol levels.6 However, it has also been
reported that some cancer cells, including prostate cancer PC-
3 cells, lack feedback regulation of LDLr, which provides an extra
energy source to promote their uncontrolled growth.7
In this study, we evaluated the relationship between LDLr
expression and the inhibition of androgen-dependent andy Elsevier. This is an open access article under the CC BY-NC-ND license (http://
Fig. 1. Effects of simvastatin on prostate cancer cell proliferations. (A, B) Cells were
incubated with simvastatin-containing media. The inhibitor effects of simvastatin on
cell proliferation were evaluated at 48 hours with MTS assay. Data are expressed as
mean ± SD (n ¼ 4). a)P < 0.01 versus simvastatin 0mM.
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treatment with statins. LDLr has been shown to play an important
role in the statin-induced inhibition of prostate cancer cell prolif-
eration. These results suggest that statins could be more effective
against androgen-independent prostate cancer, inwhich regulation
of LDLr expression is lost.
2. Materials and methods
2.1. Cells and chemicals
The human prostate cancer cell lines PC-3 and LNCaP were
purchased from Dainippon Pharmaceutical (Tokyo, Japan) and
cultured in Roswell Park Memorial Institute-1640 (Sigma-Aldrich,
St. Louis, MO, USA) supplemented with 10% fetal bovine serum
(FBS; Moregate, Bulimba, Australia). Antibodies (rabbit anti-LDLr
polyclonal antibody and rabbit antihuman b-actin monoclonal
antibody) were purchased from Cell Signaling (Beverly, MA, USA)
and Epitomics (Burlingame, CA, USA), respectively. Simvastatinwas
purchased from Sigma-Aldrich.
2.2. Cell proliferation assay of human prostate cancer cells
Cells were seeded in a 96-well microtiter plate in 100 mL of
medium, with 10% FBS, for 48 hours. Then, the medium was aspi-
rated and the cells were incubated with a medium containing
various concentrations of simvastatin. After incubation at 37C in
5% CO2 for 48 hours, the number of living cells was measured, using
the MTS assay (CellTiter 96 AQueous One Solution cell proliferation
assay; Promega, Madison, WI, USA). The optical density of the cell
lysate was expressed as fold change.
2.3. Quantiﬁcation of messenger RNA levels
Messenger RNA (mRNA) levels were quantiﬁed using the CFX96
Real-Time System (Bio-Rad, Hercules, CA, USA). Total RNA extrac-
tion and complementary DNA (cDNA) synthesis were then per-
formed8; polymerase chain reaction (PCR) ampliﬁcation was done
using 2 mL of cDNA, LDLr primer (No. Hs01092525_m1, Applied
Biosystems, Waltham, MA, USA). Next, PCR was performed for one
cycle of 10 minutes at 95C followed by 40 cycles of 15 seconds at
95C and 60 seconds at 60C. For the internal control, b-actin (No.
4326315E, Applied Biosystems) transcript levels were used. Quan-
titation of mRNA fold changes was made using the comparative CT
(2DDCt) cycle (DCt) method.9
2.4. Western blotting assays
Cell lysates were prepared in radioimmunoprecipitation assay
buffer (Pierce, Rockford, IL, USA), containing protease inhibitors
(complete, without EDTA; Roche Diagnostics, Penzberg, Germany).
Equal amounts of protein (30‒40 mg/lane) were electrophoresed on
4‒12% sodium dodecyl sulfateepolyacrylamide gel and transferred
onto nitrocellulose membranes. Each membrane was incubated
with the aforementioned primary antibodies. Blots were developed
with a 1:1,000 dilution of the horseradish peroxidase-conjugated
secondary antibody (Cell Signaling). Proteins were visualized us-
ing the Immobilon Western HRP Reagent (Millipore, Billerica, MA,
USA). A representative experiment of three independent experi-
ments is shown in each ﬁgure.
2.5. Measurement of total cholesterol levels in vitro
Cells were cultured in a 6-well plate and incubated overnight in
medium containing 10% FBS. Cells were then incubated in a culturemedium containing various concentrations of simvastatin. After
72 hours, the medium was aspirated, and cells were washed with
PBS. Cholesterol was extracted with hexane:isopropanol (3:2, v/v),
and the solution was transferred to glass tubes for drying by
evaporation. Once the tube was dried, 200 mL of 50mM Tris con-
taining 0.1% Triton X-100 and 10mM sodium cholate was added to
the tube, and cholesterol concentrations were measured enzy-
matically (Wako, Osaka, Japan). In addition, a solution of 0.1% so-
dium dodecyl sulfate plus 0.1N NaOH was applied to the wells and
the protein concentration was measured using a DC protein assay
(Bio-Rad). The total cholesterol level was calculated by dividing the
result by the total protein concentration.
2.6. Small interfering RNA
Cells were transfected with ON-TARGETplus Nontargeting Pool
(No. D-001810-10-05, Dharmacon, Waltham, MA, USA) and ON-
TARGETplus LDLr small interfering RNA (siRNA; No. L-011073-00-
0005, Dharmacon) using DharmaFect (Dharmacon). After trans-
fection, the cells were incubated for 48 hours at 37C in a 5% CO2
atmosphere.
2.7. Statistical analysis
All data are expressed as means ± standard deviation unless
otherwise indicated. Differences between values were evaluated by
one-way analysis of variance with Tukey post hoc test. In all ana-
lyses, P < 0.05 was considered to indicate statistical signiﬁcance.
3. Results
3.1. Effect of simvastatin on prostate cancer cell proliferation
First, we examined the effects of simvastatin on prostate cancer
cell proliferation using MTS assay. The viable cell numbers of PC-
3 cells decreased signiﬁcantly after incubationwith simvastatin in a
dose-dependent manner (Fig. 1A). By contrast, simvastatin did not
inhibit the proliferation of LNCaP cells except at the high concen-
tration (100mM; Fig. 1B).
3.2. Levels of LDLr in prostate cancer cells after treatment with
simvastatin
We then evaluated the effect of simvastatin on LDLr levels in
prostate cancer cells. As shown in Fig. 2A, simvastatin signiﬁcantly
decreased LDLr mRNA expression in PC-3 cells. However, LDLr
mRNA levels signiﬁcantly increased after simvastatin treatment in
LNCaP cells. In the same manner as mRNA, LDLr protein levels also
Fig. 2. Low-density lipoprotein receptor (LDLr) expression levels in prostate cancer
cells after treatment with simvastatin. (A, B) Cells were incubated with simvastatin-
containing media. RNA samples were extracted and assayed by quantitative real-
time polymerase chain reaction. Data are expressed as means ± SD (n ¼ 5).
a)P < 0.01 versus 0mM. (C, D) Cells were incubated in simvastatin simvastatin-
containing media for 48 hours and analyzed for LDLr protein levels by Western blot-
ting. Beta-actin protein levels were used as the internal control. Sim, simvastatin.
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remained unchanged after simvastatin treatment (Fig. 2C).3.3. Intracellular cholesterol levels in prostate cancer cells after
simvastatin treatment
Cholesterol levels are known to affect prostate cancer cell pro-
liferation.10 In PC-3 cells, simvastatin decreased intracellular
cholesterol levels in a dose-dependent manner (Fig. 3A). However,
LNCaP cells appeared to be resistant to any change in intracellular
cholesterol levels with simvastatin (Fig. 3B).Fig. 3. Total cholesterol mass after 72-hour treatment with various concentrations of
simvastatin. (A, B) Data are expressed as means ± SD (n ¼ 3). a)P < 0.01, versus 0mM.3.4. Effects of LDLr knockdown on LNCaP cells treated with
simvastatin
To further determine whether LDLr plays an important role in
the statin-induced inhibition of prostate cancer cell proliferation,
LDLr expression was reduced by transfection with a siRNA against
LDLr. The amount of LDLr protein was reduced markedly by the
siRNA (Fig. 4A). The reduced level of LDLr in LNCaP cells following
siRNA transfection was associated with decreased intracellular
cholesterol levels after treatment with simvastatin (Fig. 4B). Sim-
vastatin also inhibited LNCaP cell proliferation after transfection of
the siRNA (Fig. 4C), consistent with the known role of intracellular
cholesterol in cell proliferation.
4. Discussion
In this study, we showed that the mechanism of the effect of
simvastatin on prostate cancer cells depends on the expression of
LDLr. It has been reported that statins inhibit the development of
prostate cancer cells, but the mechanism has not been clear. To the
best of our knowledge, this is the ﬁrst report showing that the LDLr
plays an important role in the statin-induced inhibition of prostate
cancer cell proliferation.
Statins are taken by many hyperlipidemic patients worldwide.
In addition, statins have been investigated for carcinoma preven-
tion or as cures for cancer. There are many clinical reports on the
relationship between statins and prostate cancer outcomes.
Recently, large population-based retrospective cohort studies
showed that the use of statins after diagnosis was associated with a
decreased risk of prostate cancer mortality11; furthermore, statin
use was associated with a reduced risk for prostate cancer.2 Con-
cerning the outcomes after radical therapy, statin use was associ-
ated with reductions in the risk of biochemical recurrence after
both radical prostatectomy12 and radiation therapy.13 However, it is
reported that the use of statins did not reduce the risk of prostate
cancer overall, but was associated with a reduced risk of advanced
(especially metastatic or fatal) prostate cancer.14 We showed that
simvastatin had more antitumor effects on androgen-independent
than on androgen-dependent prostate cancer cells. These ﬁndings
indicate that statins may reduce the development of more
aggressive prostate cancers.
The expression of LDLr is regulated by intracellular cholesterol
levels in normal cells. Lipoprotein treatment decreased LDLr
expression to prevent too much cholesterol from entering normal
cells.6 However, LDLr expression is increased by statins, which
inhibit HMG-CoA reductase and decrease intracellular cholesterol
levels. As a result, statins reduce blood cholesterol levels by
increasing LDL uptake.15 In this study, LDLr expression in LNCaP
cells was increased by simvastatin, as in normal cells, but not in PC-
3 cells. Regarding prostate cancer, PC-3 and DU145 cells are re-
ported to lack feedback regulation of sterol regulatory element-
binding protein-2 (SREBP2), which controls LDLr expression in
accordance with intracellular cholesterol levels; the lack of SREBP2
feedback is at least in part explained by the lack of LDLr feedback in
the cells.7 It was also reported that androgens regulate lipogenesis
through activation of the SREBP pathway in prostate cancer,16 and
dysregulation of SREBPs by androgens occurred during progression
to androgen independence in LNCaP cells.17 Chen and Hughes-
Fulford7 and Sekine et al18 have shown that LDL and remnant li-
poproteins downregulated LDLr expression in LNCaP cells, but not
in PC-3 cells. In this study, androgen-dependent LNCaP cells were
able to regulate LDLr expression in response to simvastatin,
whereas androgen-independent PC-3 cells could not. Thus, we
suggest that androgen dependency has an important role in the
regulation of LDLr expression in prostate cancer cells.
Fig. 4. Effect of low-density lipoprotein receptor (LDLr) knockdown on LNCaP cells treated with simvastatin. (A) Transfection of LNCaP cells with LDLr small interfering RNA (siRNA)
or negative siRNA was performed as described in the “Materials and Methods” section. After transfection, the cells were incubated for 48 hours before harvesting for Western
blotting. Negative siRNA-transfected cells were used as controls. (B) After transfection, the cells were incubated with simvastatin-containing media. The total cholesterol mass was
evaluated after 72 hours of treatment with various concentrations of simvastatin. Values are expressed as the means ± SD (n ¼ 3). a)P < 0.01, vs. 0mM. (C) After transfection, the cells
were incubated with simvastatin-containing media. The number of viable cells was evaluated using MTS assay after 48 hours of treatment with various concentrations of sim-
vastatin. Values are expressed as means ± SD (n ¼ 3). a)P < 0.05 versus 0mM. b)P < 0.01 versus 0mM.
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bolism, and cell signaling in cellular proliferation. Clinically, it has
been shown that high cholesterol levels are associated with an
increased risk of aggressive prostate cancer.19,20 In addition,
cholesterol promotes prostate cancer cell line growth in vitro and in
xenograft models by inducing Akt activation21 and de novo ste-
roidogenesis.22 We showed that simvastatin inhibited cell prolif-
eration and decreased cellular cholesterol levels in PC-3 cells,
which could not increase LDLr expression sufﬁciently to cover the
deﬁciency in cellular cholesterol after treatment with simvastatin.
In addition, the reduced level of LDLr in LNCaP cells following siRNA
transfection was associated with decreased cellular cholesterol
levels and basal cell proliferation. Murtola et al23 reported that
simvastatin inhibited LNCaP cell proliferation in culture medium
without cholesterol, and the effect was prevented by LDL. These
ﬁndings indicate that a decrease in cholesterol levels is one of the
mechanisms underlying statin-induced inhibition of prostate can-
cer cells.
Our study had several limitations. First, the clinical plasma
concentrations of statins are in the range of 10‒100nM24 but the
concentration in prostate tissue is unknown. Thus, there is a pos-
sibility that our experimental concentration of simvastatin was
unrealistically high. Furthermore, we evaluated the effect of statins
only in vitro. Despite these limitations, the results are interesting
because there has been no previous report of any relationship be-
tween the antitumor effects of statins and LDLr expression in
prostate cancer.
In summary, statins inhibited prostate cancer cell growth by
decreasing cellular cholesterol, and they could be more effective
against androgen-independent prostate cancer, in which there is
loss of regulation of LDLr expression. Besides, androgen-
deprivation therapy for prostate cancer is well-known to
signiﬁcantly increase the levels of total cholesterol and tri-
glycerides.25 These results suggest that statins have the clinical
potentials of not only improving hyperlipidemia, but also
inhibiting the progression of castration refractory prostate can-
cer. Future studies on the cholesterol-lowering effects of statins
may lead to new approaches for the prevention and treatment of
prostate cancer.Conﬂicts of interest
All authors have no disclosures to declare.Acknowledgments
The work was supported in part by Promotion Plan for the
Platform of Human Resource Development for Cancer.We thankMs
Atusko Oyama and Ms Hayumi Oayama for their technical
assistance.
References
1. Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-
CoA reductase. Science 2001;292:1160e4.
2. Farwell WR, D'Avolio LW, Scranton RE, Lawler EV, Gaziano JM. Statins and
prostate cancer diagnosis and grade in a veterans population. J Natl Cancer Inst
2011;103:885e92.
3. Chang CC, Ho SC, Chiu HF, Yang CY. Statins increase the risk of prostate cancer:
a population-based case-control study. Prostate 2011;71:1818e24.
4. Hoque A, Chen H, Xu XC. Statin induces apoptosis and cell growth arrest in
prostate cancer cells. Cancer Epidemiol Biomarkers Prev 2008;17:88e94.
5. Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR. Cholesterol targeting
alters lipid raft composition and cell survival in prostate cancer cells and xe-
nografts. J Clin Invest 2005;115:959e68.
6. Tam SP, Brissette L, Ramharack R, Deeley RG. Differences between the regu-
lation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and low density
lipoprotein receptor in human hepatoma cells and ﬁbroblasts reside primarily
at the translational and post-translational levels. J Biol Chem 1991;266:
16764e73.
7. Chen Y, Hughes-Fulford M. Human prostate cancer cells lack feedback regu-
lation of low-density lipoprotein receptor and its regulator, SREBP2. Int J
Cancer 2001;91:41e5.
8. Suzuki K, Koike H, Matsui H, Ono Y, Hasumi M, Nakazato H, et al. Genistein, a
soy isoﬂavone, induces glutathione peroxidase in the human prostate cancer
cell lines LNCaP and PC-3. Int J Cancer 2002;99:846e52.
9. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-
time quantitative PCR and the 2DDCT method. Methods 2001;25:402e8.
10. Sun Y, Sukumaran P, Varma A, Derry S, Sahmoun AE, Singh BB. Cholesterol-
induced activation of TRPM7 regulates cell proliferation, migration, and
viability of human prostate cells. Biochim Biophys Acta 2014;1843:1839e50.
11. Yu O, EbergM, Benayoun S, Aprikian A, Batist G, Suissa S, et al. Use of statins and
the risk of death in patients with prostate cancer. J Clin Oncol 2014;32:5e11.
12. Hamilton RJ, Banez LL, Aronson WJ, Terris MK, Platz EA, Kane CJ, et al. Statin
medication use and the risk of biochemical recurrence after radical prosta-
tectomy: results from the Shared Equal Access Regional Cancer Hospital
(SEARCH) Database. Cancer 2010;116:3389e98.
13. Gutt R, Tonlaar N, Kunnavakkam R, Karrison T, Weichselbaum RR, Liauw SL.
Statin use and risk of prostate cancer recurrence in men treated with radiation
therapy. J Clin Oncol 2010;28:2653e9.
14. Platz EA, Leitzmann MF, Visvanathan K, Rimm EB, Stampfer MJ, Willett WC,
et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst
2006;98:1819e25.
15. Brown MS, Goldstein JL. Lowering plasma cholesterol by raising LDL receptors.
N Engl J Med 1981;305:515e7.
16. Heemers H, Maes B, Foufelle F, Heyns W, Verhoeven G, Swinnen JV. Androgens
stimulate lipogenic gene expression in prostate cancer cells by activation of the
sterol regulatory element-binding protein cleavage activating protein/sterol
Prostate Int 4 (2016) 56e6060regulatory element-binding protein pathway. Mol Endocrinol 2001;15:
1817e28.
17. Ettinger SL, Sobel R, Whitmore TG, Akbari M, Bradley DR, Gleave ME, et al.
Dysregulation of sterol response element-binding proteins and downstream
effectors in prostate cancer during progression to androgen independence.
Cancer Res 2004;64:2212e21.
18. Sekine Y, Koike H, Nakano T, Nakajima K, Takahashi S, Suzuki K. Remnant
lipoproteins induced proliferation of human prostate cancer cell, PC-3 but
not LNCaP, via low density lipoprotein receptor. Cancer Epidemiol 2009;33:
16e23.
19. Platz EA, Till C, Goodman PJ, Parnes HL, Figg WD, Albanes D, et al. Men with low
serum cholesterol have a lower risk of high-grade prostate cancer in the pla-
cebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers
Prev 2009;18:2807e13.
20. Shaﬁque K, McLoone P, Qureshi K, Leung H, Hart C, Morrison DS. Cholesterol
and the risk of grade-speciﬁc prostate cancer incidence: evidence from twolarge prospective cohort studies with up to 37 years' follow up. BMC Cancer
2012;19:12e25.
21. Zhuang L, Lin J, Lu ML, Solomon KR, Freeman MR. Cholesterol-rich lipid rafts
mediate AKT-regulated survival in prostate cancer cells. Cancer Res 2002;62:
2227e31.
22. Mostaghel EA, Solomon KR, Pelton K, Freeman MR, Montgomery RB. Impact of
circulating cholesterol levels on growth and intratumoral androgen concen-
tration of prostate tumors. PLoS One 2012;7:e30062.
23. Murtola TJ, Syv€al€a H, Pennanen P, Bl€auer M, Solakivi T, Ylikomi T, et al. The
importance of LDL and cholesterol metabolism for prostate epithelial cell
growth. PLoS One 2012;7:e39445.
24. Pan HY, DeVault AR, Wang-Iverson D, Ivashkiv E, Swanson BN, Sugerman AA.
Comparative pharmacokinetics and pharmacodynamics of pravastatin and
lovastatin. J Clin Pharmacol 1990;30:1128e35.
25. Saylor PJ, Smith MR. Metabolic complications of androgen deprivation therapy
for prostate cancer. J Urol 2009;181:1998e2008.
